Anupam Rasayan India Ltd

The transcript from the earnings call of Anupam Rasayan India Limited does not mention any current or planned fundraising through debt or equity. Key points related to financing include: - No discussion or announcements about new debt or equity fundraising during the call. - Focus is on organic growth through acquisitions (e.g., Jayhawk Fine Chemicals) and operational scale-up. - The company aims for disciplined, long-term value creation without mentioning dilution or additional borrowings. - Working capital optimization is a priority to improve cash flow and financial efficiency. Thus, based on the available transcript, there are no indications of immediate or planned fundraising activities via debt or equity for FY27 or FY28 at this time.

- The transcript does not explicitly mention any specific current or future capex or strategic capital investment plans. - However, it highlights the strategic acquisition of Jayhawk Fine Chemicals, a US-based specialty chemicals company, expected to close soon, which represents a significant capital investment expanding Anupam's footprint in the US. - This acquisition strengthens supply chain presence, technology, customer base, and product portfolio across high-value sectors like semiconductors, pharma, EV, and aerospace. - The company also focuses on ramping up capacity utilization across manufacturing assets and smoothly integrating Jayhawk, implying ongoing investments in operational expansion. - No detailed future capex figures or new plant/equipment investments were disclosed in the available transcript. - The management emphasizes growth driven by expanding global footprints, pipeline commercialization, and technology enhancement, indicating possible capex aligned with these goals going forward.

- Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. - Management optimistic about continuing growth into FY27, driven by robust pipeline and deepening global customer relationships. - Expansion supported by scaling up commercial molecules and ramping up capacity utilization. - Focus on ramping up Pharma and Performance Material portfolios, which showed significant growth (Pharma up 85%, Performance Materials up 245% YoY for 9MFY26). - Pipeline includes 65+ molecules in R&D/pilot stages, supporting future revenue growth. - Acquisition of Jayhawk Fine Chemicals to strengthen North America footprint, expanding access to innovation-driven sectors (semiconductors, automotive, pharma, EV). - Working capital management aims to reduce intensity from ~250 days to below 200 days by FY27, enhancing operational efficiency. - Long-term value creation through expanding fluorination chemistry capabilities and supply chain resilience.

- Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints. - The acquisition of Jayhawk Fine Chemicals is expected to be EPS accretive from day one, enhancing revenue and profitability through expanded US market presence and new customer validations. - Management targets improvement in working capital days to below 200 by FY27, aiming around 180 days to improve cash flow and operational efficiency. - Revenue growth drivers include ramp-up of commercial molecules, expanded fluorination chemistry capabilities, and increasing demand in Pharma, Performance Materials, and advanced materials sectors. - EBITDA margins remain healthy, around 23-25%, with a focus on cost and process optimization, leveraging backward integration (e.g., Tanfac) and technology enhancements. - Long-term value creation is driven by high entry barrier chemistries, complex syntheses, and sustained global customer stickiness, supporting disciplined earnings expansion.

- In 9MFY26, Letters of Intent (LOIs) and contracts contributed over INR 250 crores of revenue, indicating strong conversion of the order pipeline into commercial revenue. - The company has a robust pipeline with over 65 molecules across R&D and pilot stages in Pharma and Polymer segments. - The Pharma segment has more than 30 molecules under development and pilot stages. - The Polymer and Electronic Material vertical has 35+ molecules in development and pilot stages. - The strong customer pipeline and order book visibility support optimistic growth momentum into the next fiscal year.